- NVO +3.51% ^GSPC +0.69% ^IXIC +0.82%
Key Points
-
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose.
-
The application is under expedited FDA review, with a decision expected within one to two months.
-
10 stocks we like better than Novo Nordisk ›
Shares of Novo Nordisk (NYSE: NVO) are gaining on Monday, up 3.5% as of 2:40 p.m. ET. The jump comes as the S&P 500 and the Nasdaq Composite gained 0.8% and 0.9%, respectively.
The Danish drugmaker submitted an application today seeking regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.
Novo wants to sell a bigger dose of Wegovy
Just days after a failed Alzheimer's trial sent Novo shares lower, today's regulatory filing revealed the company is seeking the Food and Drug Administration's (FDA) approval for a larger dose of Wegovy. The increased dose -- nearly three times the current maximum dose -- has shown promising results in trials lasting more than a year; participants lost an average of 20.7% of their body weight, compared to 15% in its current form.
Image source: Getty Images. The application is part of an expedited review process at the FDA, and a decision is expected within one to two months.
Novo stock is well-priced
The company's stock has been beaten down with a string of bad news and growing competition in the obesity and weight loss markets. I think it's been oversold. And while the road ahead will be bumpy, I think Novo Nordisk is a great long-term hold.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $563,022!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,012!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 24, 2025
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Why Novo Nordisk Stock Is Moving Higher Today was originally published by The Motley Fool
Terms and Privacy Policy Privacy Dashboard More Info
